MTMeghna Das Thakur

Meghna Das Thakur

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Meghna Das Thakur has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Akshata R. Udyavar

    Affiliation Bioinformatics & Computational Biology, Genentech Inc., South San Francisco, California, United States of America

    1 shared publication
  • Alexandre Vasiljevic

    Team Fluid, INSERM U1028, CNRS UMR 5292, Lyon Neurosciences Recherche Center, Université Lyon 1, Lyon, France

    1 shared publication
  • Amelia Au-Yeung

    Affiliation Oncology Biomarker Development, Genentech Inc., South San Francisco, California, United States of America

    1 shared publication
  • Anneleen Daemen

    Department of Bioinformatics & Computational Biology, Genentech, Inc

    1 shared publication
  • Aurelien Marabelle

    University of Paris Saclay, Gustave Roussy Cancer Center, Villejuif, France

    1 shared publication
  • Carl J. Franz

    Lake Tahoe Community College, South Lake Tahoe, CA, USA

    1 shared publication

Latest Publications

  • Immune contexture of paediatric cancers

    by Meghna Das Thakur, Carl J. Franz, Laura Brennan, Jurriaan Brouwer-Visser, Rachel Tam, Konstanty Korski, Hartmut Koeppen, James Ziai, Galina Babitzki, Dominique Ranchere-Vince, et al.


  • Open Access

    Transcriptomic profiling of adjuvant colorectal cancer identifies three key prognostic biological processes and a disease specific role for granzyme B

    by Anneleen Daemen, Akshata R. Udyavar, Thomas Sandmann, Congfen Li, Linda J. W. Bosch, William O’gorman, Yijin Li, Amelia Au-Yeung, Chikara Takahashi, Omar Kabbarah, et al.

    Background: Colorectal cancer (CRC) is a leading cause of cancer-related deaths, with a 5% 5-year survival rate for metastatic disease, yet with limited therapeutic advancements due to insufficient understanding of and inability to accurately capture high-risk CRC patients who are most likely to recur. We aimed to improve high-risk classification by identifying biological pathways associated with outcome in adjuvant stage II/III CRC. Methods and findings: We included 1062 patients with stage III or high-risk stage II colon carcinoma from the prospective three-arm randomized phase 3 AVANT trial, and performed expression profiling to identify a prognostic signature. Data from validation cohort GSE39582, The Cancer Genome Atlas, and cell lines were used to further validate the prognostic biology. Our retrospective analysis of the adjuvant AVANT trial uncovered a prognostic signature capturing three biological functions—stromal, proliferative and immune—that outperformed the Consensus Molecular Subtypes (CMS) and recurrence prediction signatures like Oncotype Dx in an independent cohort. Importantly, within the immune component, high granzyme B (GZMB) expression had a significant prognostic impact while other individual T-effector genes were less or not prognostic. In addition, we found GZMB to be endogenously expressed in CMS2 tumor cells and to be prognostic in a T cell independent fashion. A limitation of our study is that these results, although robust and derived from a large dataset, still need to be clinically validated in a prospective study. Conclusions: This work furthers our understanding of the underlying biology that propagates stage II/III CRC disease progression and provides scientific rationale for future high-risk stratification and targeted treatment evaluation in biomarker defined subpopulations of resectable high-risk CRC. Our results also shed light on an alternative GZMB source with context-specific implications on the disease’s unique biology.